KemPharm (NASDAQ:KMPH) has been assigned a $9.00 target price by investment analysts at Royal Bank of Canada in a note issued to investors on Tuesday. The firm presently has a “buy” rating on the specialty pharmaceutical company’s stock. Royal Bank of Canada’s price objective points to a potential upside of 76.47% from the stock’s current price.
Several other equities analysts have also recently weighed in on the company. Zacks Investment Research raised KemPharm from a “hold” rating to a “buy” rating and set a $4.25 target price on the stock in a research note on Wednesday, November 15th. ValuEngine raised KemPharm from a “strong sell” rating to a “sell” rating in a research note on Sunday, December 31st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $8.35.
KemPharm (NASDAQ KMPH) traded up $0.15 during trading hours on Tuesday, reaching $5.10. The company’s stock had a trading volume of 60,200 shares, compared to its average volume of 81,391. The company has a current ratio of 7.56, a quick ratio of 7.56 and a debt-to-equity ratio of -1.92. KemPharm has a 52 week low of $2.45 and a 52 week high of $5.40. The stock has a market cap of $74.75 and a PE ratio of -1.75.
In other KemPharm news, EVP Daniel L. Cohen bought 7,500 shares of the stock in a transaction on Monday, November 27th. The shares were bought at an average price of $3.79 per share, with a total value of $28,425.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 25.40% of the company’s stock.
A hedge fund recently raised its stake in KemPharm stock. Alyeska Investment Group L.P. grew its position in shares of KemPharm, Inc. (NASDAQ:KMPH) by 1.8% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 992,338 shares of the specialty pharmaceutical company’s stock after buying an additional 17,721 shares during the quarter. Alyeska Investment Group L.P. owned approximately 6.77% of KemPharm worth $3,672,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 36.04% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://www.americanbankingnews.com/2018/01/17/kempharm-kmph-given-a-9-00-price-target-at-royal-bank-of-canada.html.
KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.